Table 1.
Predictors of patient satisfaction with antipsychotic medication
| Day 14 | Day 42 (end point) | |||||||||
| Univariate regression | Step-wise multiple regression R2 = .31 | Univariate regression | Step-wise multiple regression R2 = .33 | |||||||
| T = | p = | R2 | F = | p = | T = | p = | R2 | F = | p = | |
| Symptom change PANSS factors Positive | -10.11 | <.0001 | .26 | 21.98 | <.0001 | -9.40 | <.0001 | .23 | 6.39 | .01 |
| Negative | -5.22 | <.0001 | .11 | -5.69 | <.0001 | .12 | 3.63 | .06 | ||
| Disorganized thoughts | -5.89 | <.0001 | .13 | -5.64 | <.0001 | .12 | ||||
| Hostility/excitement | -9.25 | <.0001 | .23 | 14.11 | .0002 | -8.69 | <.0001 | .21 | 12.46 | .0005 |
| Anxiety/depression | -5.80 | <.0001 | .13 | 4.03 | .04 | -7.43 | <.0001 | .17 | 16.85 | <.0001 |
| HAM-D | -5.33 | <.0001 | .11 | NS | -5.06 | <.0001 | .11 | NS | ||
| Adverse events Prolactin level | .439 | .66 | .04 | -.666 | .50 | .04 | NS | |||
| EPS reported | -.95 | .34 | .04 | 2.89 | .09 | .60 | .55 | .04 | NS | |
| Sedation reported | -1.21 | .23 | .05 | 1.91 | .06 | .05 | NS | |||
| BAS global (present) | -1.42 | .16 | .05 | -.88 | .38 | .04 | ||||
| SAS total (present) | -.50 | .62 | .04 | -.25 | .80 | .04 | ||||
| Demographics Age | 1.84 | .07 | .05 | 6.17 | .01 | .58 | .56 | .04 | ||
| Gender (male) | .46 | .64 | .04 | .37 | .71 | .04 | ||||
| Antipsychotic use | NA* | -2.69 | .007 | .06 | 8.03 | .004 | ||||
| Risperidone | 3.48 | .0006 | .04 | 4.80 | .03 | 3.06 | .002 | 4.94 | .027 | |
| Quetiapine | 1.15 | .25 | .04 | .60 | .44 | .83 | .41 | .00 | .98 | |
* Antipsychotic use appeals after 14 days.
Abbreviations: PANSS, Positive and Negative Syndrome Scale; HAM-D, Hamilton Depression Scale; NS, not significant; EPS, extrapyramidal symptoms; BAS, Barnes Akathisia Scale; SAS, Simpson Angus Scale.